A striking 18% of hepatitis B patients achieved functional cure using GSK’s experimental bepirovirsen, compared to just 1% with current standard therapies—an 18-fold improvement with profound implications for global hepatitis B management. This data emerges from phase 2 clinical trials presented at recent medical conferences, where functional cure was defined as sustained suppression of hepatitis B surface antigen for at least 24 weeks following treatment completion. For the 296 million people worldwide living with chronic hepatitis B, this disparity represents a potential paradigm shift in clinical practice. The drug’s novel antisense RNA approach directly targets viral replication mechanisms, offering a fundamentally different strategy from existing nucleoside analogues. These compelling results underscore the urgent need for advanced therapeutics in hepatitis B care and signal promising prospects for upcoming phase 3 trials. Read the full article on GMJ Newsroom.
Was this article helpful?
